Subodh Verma

MD, FRCSC, FAHA, PhD

Scientist

Biography

Please note: Dr. Verma will not take students in summer.

Dr Subodh Verma is an internationally renowned cardiac surgeon-scientist and Professor at the
University of Toronto. He is the Canada Research Chair in Cardiovascular Surgery and a past
recipient of the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research
and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. He previously
served as the Canada Research Chair in Atherosclerosis (2007-2017). He is an appointee of the
American Association of Thoracic Surgeons (AATS) and a member of the College of New Scholars,
Artists and Scientists, Royal Society of Canada. According to Google Scholar in December 2020, Dr
Verma has an h-index of 107 and his work has been cited over 58,000 times.

Dr Verma has published extensively in prestigious journals like the NEJM, Lancet, Circulation, JACC,
Nature, and JCI and he is currently an Associate Editor of the European Heart Journal. Dr Verma is
an active contributor to Canadian clinical practice guidelines and recently co-authored the
recommendations for atrial fibrillation, antiplatelet therapy, heart failure and diabetes; he was a
member of the 2018 AATS consensus guidelines committee on bicuspid aortic valve-related
aortopathy. Dr Verma has served in various capacities on the American Heart Association Council
on Cardiovascular Surgery and Anesthesia since 2008.

Dr Verma has leadership roles on 7 global heart failure trials in diabetes – DAPA-HF, DELIVER,
DETERMINE-A, DETERMINE-B, EMPEROR-Preserved, EMPEROR-Reduced and SOLOIST-WHF.
He is also involved in the DAPA ACT HF-TIMI 68, FINEARTS-HF, STEP HFpEF, VESALIUS-CV,
DARE-19, SELECT and CLEAR SYNERGY trials. He founded and oversees the CardioLink platform
at St Michael’s Hospital that is conducting cardiometabolic and surgically oriented RCTs and
translational studies.

Dr Verma leads a dynamic pre-clinical and translational research team that leverages pre-clinical
disease models and clinical trial-derived data to identify novel mediators of cardiovascular and
cardiometabolic disease as well as answer timely and relevant healthcare questions. His research
has yielded 2 United States patents and is supported by several national peer-reviewed grants.

 

Recent Publications

  1. Goldenberg, RM, Cheng, AYY, Gilbert, JD, Lonn, EM, Pedersen, SD, Verma, S et al.. The role of icosapent ethyl in cardiovascular risk reduction. Curr Opin Cardiol. 2021; :. doi: 10.1097/HCO.0000000000000873. PubMed PMID:33929367 .
  2. Jhund, PS, Ponikowski, P, Docherty, KF, Gasparyan, SB, Böhm, M, Chang, CE et al.. Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure with Reduced Ejection Fraction: An Analysis of DAPA-HF. Circulation. 2021; :. doi: 10.1161/CIRCULATIONAHA.121.053659. PubMed PMID:33832352 .
  3. Terenzi, DC, Verma, S, Hess, DA. Exploring the Clinical Implications of Wnt Signaling in Enucleated Erythrocytes. Arterioscler Thromb Vasc Biol. 2021;41 (5):1654-1656. doi: 10.1161/ATVBAHA.121.316169. PubMed PMID:33792347 .
  4. Verma, S, Fainberg, U, Husain, M, Rasmussen, S, Rydén, L, Ripa, MS et al.. Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide. Diabetes Obes Metab. 2021; :. doi: 10.1111/dom.14360. PubMed PMID:33606902 .
  5. Berg, DD, Jhund, PS, Docherty, KF, Murphy, SA, Verma, S, Inzucchi, SE et al.. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. 2021; :. doi: 10.1001/jamacardio.2020.7585. PubMed PMID:33595593 PubMed Central PMC7890451.
  6. Butt, JH, Nicolau, JC, Verma, S, Docherty, KF, Petrie, MC, Inzucchi, SE et al.. Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. Eur J Heart Fail. 2021; :. doi: 10.1002/ejhf.2124. PubMed PMID:33594755 .
  7. Terenzi, DC, Bakbak, E, Trac, JZ, Al-Omran, M, Quan, A, Teoh, H et al.. Isolation and characterization of circulating pro-vascular progenitor cell subsets from human whole blood samples. STAR Protoc. 2021;2 (1):100311. doi: 10.1016/j.xpro.2021.100311. PubMed PMID:33554145 PubMed Central PMC7856468.
  8. Luu, AZ, Luu, VZ, Chowdhury, B, Kosmopoulos, A, Pan, Y, Al-Omran, M et al.. Loss of endothelial cell-specific autophagy-related protein 7 exacerbates doxorubicin-induced cardiotoxicity. Biochem Biophys Rep. 2021;25 :100926. doi: 10.1016/j.bbrep.2021.100926. PubMed PMID:33553688 PubMed Central PMC7851775.
  9. Cherney, DZI, Verma, S. DAPA-CKD: The Beginning of a New Era in Renal Protection. JACC Basic Transl Sci. 2021;6 (1):74-77. doi: 10.1016/j.jacbts.2020.10.005. PubMed PMID:33532667 PubMed Central PMC7838045.
  10. Verma, S, Mazer, CD, Inzucchi, SE, Wanner, C, Ofstad, AP, Johansen, OE et al.. Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME. Diabetes Obes Metab. 2021;23 (5):1173-1181. doi: 10.1111/dom.14326. PubMed PMID:33502090 .
Search PubMed

Affiliations & Other Activities

  • Staff Surgeon, Division of Cardiology , St. Michael’s Hospital
  • Professor, Department of Surgery and Pharmacology & Toxicology, University of Toronto
X